ARA-290 is a non-erythropoietic EPO receptor agonist studied for neuroprotection, anti-inflammation, tissue repair, and peripheral nerve recovery. Physician-reviewed. Prescription required.
ARA-290 is a synthetic peptide derived from the tissue-protective region of Erythropoietin. It was designed to retain EPO's cytoprotective and anti-inflammatory effects without stimulating red blood cell production. Its mechanisms involve activation of a distinct receptor complex that triggers tissue protection, anti-inflammation, and repair pathways.
This selectivity allows ARA-290 to deliver cytoprotective, anti-inflammatory, and repair-promoting effects without the hematopoietic side effects of full EPO. It has been studied in neuropathic pain, sarcoidosis, and tissue protection contexts. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Activation of tissue-protective EPO receptor subunits | Cytoprotection without erythropoiesis |
| Anti-inflammatory signaling | Reduced cytokines & immune activation |
| Anti-apoptotic pathways (PI3K/Akt) | Enhanced cell survival |
| Immunomodulation | Lower chronic inflammation |
| Endothelial support | Improved microvascular function |
| Repair/regeneration signals | Tissue recovery |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with ARA-290 protocol candidates in clinical practice:
Neuropathic Pain
Individuals with physician-confirmed neuropathic pain where ARA-290's TPR activation may be clinically relevant.
Nerve Recovery
Individuals recovering from peripheral nerve injury or damage under physician supervision.
Inflammatory Conditions
Individuals with chronic inflammatory conditions where non-erythropoietic EPO receptor activation may support tissue protection.
Recovery Protocol
Individuals with tissue damage or vascular compromise seeking physician-supervised cytoprotective support.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
4 mg 3x/week
Administration
Subcutaneous injection
Duration
4–12 weeks (physician-determined)
Frequency
3x weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your ARA-290 protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
ARA-290 (Cibinetide) is a tissue-protective peptide studied for neuropathic pain, small fiber neuropathy, and metabolic conditions. It activates the innate repair receptor (IRR) to reduce inflammation and promote tissue healing.
ARA-290 has been studied for peripheral neuropathy, sarcoidosis-related neuropathy, diabetic neuropathy, and metabolic syndrome. It is used off-label for pain and nerve repair.
ARA-290 has a favorable safety profile in clinical studies. As with all peptide protocols at Verum Health, it is prescribed and monitored by a licensed physician.
ARA-290 is available as a subcutaneous injectable at Verum Health. Protocol length and dosing are determined by your physician based on your condition and goals.